US · LXEO
Lexeo Therapeutics, Inc. Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City 10010
- Website
- lexeotx.com
Price · as of 2024-12-31
$5.77
Market cap 524.05M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $117.37 | |||
| 2023 | $15.13 | $33.01 | |||
| 2024 | $2.70 |
AI valuation
Our deep-learning model estimates Lexeo Therapeutics, Inc. Common Stock's (LXEO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.77
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LXEO | Lexeo Therapeutics, Inc. … | $5.77 | 524.05M | — | — | — | — | -0.87 | 0.73 | — | 0.27 | -3.62 | 0.73 | 0.00% | — | — | -85.37% | -2362.17% | -68.58% | 0.08 | -927.77 | 5.52 | 5.32 | 0.26 | 2410.00% | — | 3683.00% | -95.11% | -3.55 | -1823.16% | 0.00% | 0.00% | 0.02% | 0.24 | 0.32 | — | -2.49 |
| AMRN | Amarin Corporation plc | $13.80 | 285.42M | +2,553% | -43% | -73% | +374% | -2.65 | 0.45 | 0.95 | 0.93 | -7.95 | 0.46 | 35.60% | -40.15% | -35.95% | -15.83% | -41.74% | -10.83% | 0.02 | -13113.86 | 3.31 | 2.31 | 1.53 | 3333.00% | -2551.00% | -55089.00% | -14.25% | -0.17 | -14.11% | 0.00% | 0.00% | 0.00% | 0.75 | 2.21 | -0.30 | -2.13 |
| CAPR | Capricor Therapeutics, In… | $27.93 | 1.28B | -15% | -76% | — | -88% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| CTNM | Contineum Therapeutics, I… | $15.34 | 560.36M | +1,304% | — | — | — | -3.10 | 0.66 | — | 1.61 | — | 0.66 | 0.00% | — | — | -64.95% | 27584.82% | -24.62% | 0.03 | — | 20.69 | 20.53 | 0.37 | -34222.00% | -10000.00% | -27618.00% | -25.46% | -3.29 | 18080.76% | 0.00% | 0.00% | 147.57% | 1.33 | 2.02 | — | 4.86 |
| DBVT | DBV Technologies S.A. | $20.99 | 502.12M | -17% | — | — | — | -0.71 | 2.93 | — | -0.50 | -1.28 | 2.94 | 0.00% | — | — | -135.96% | -2872.45% | -91.63% | 0.28 | — | 1.43 | 1.38 | 0.22 | 5526.00% | -10000.00% | 3297.00% | -132.98% | -3.36 | -2637.08% | 0.00% | 0.00% | 0.06% | -0.46 | -0.52 | — | -10.66 |
| KYTX | Kyverna Therapeutics, Inc… | $8.21 | 359.53M | — | — | — | — | -0.78 | 0.37 | — | 1.42 | 0.00 | 0.37 | 0.00% | — | — | -80.74% | 2732.66% | -67.12% | 0.03 | -1004.25 | 8.61 | 8.47 | 0.71 | 332990000.00% | — | 11960.00% | -116.84% | -3.38 | 2231.58% | 0.00% | 0.00% | 63.02% | 1.25 | 1.53 | — | -0.17 |
| LRMR | Larimar Therapeutics, Inc… | $5.31 | 454.48M | — | — | — | — | -2.30 | 1.08 | — | -0.08 | -4.03 | 1.08 | 0.00% | — | — | -63.58% | 3005.12% | -54.43% | 0.03 | — | 8.02 | 7.58 | 0.31 | 5714.00% | — | 11198.00% | -38.40% | -2.91 | 2356.59% | 0.00% | 0.00% | 3.72% | -0.08 | -0.10 | — | 1.56 |
| MREO | Mereo BioPharma Group plc | $0.37 | 59.17M | +8,875% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- CEO
- R. Nolan Townsend
- Employees
- 75
- Beta
- 1.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.77) − 1 = — (DCF, example).